Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review

By: via Benzinga
In a report published Wednesday, Baird analysts upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT). The price target was raised from $16 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.